Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Institute of Medicine

- PMLiVE

Alkermes depression drug misses targets in phase III

Irish firm suffers major research setback with ALKS 5461

- PMLiVE

French government begins investigation into fatal Biotrial study

First-in-man trial leaves one dead, five hospitalised

- PMLiVE

AbbVie takes ‘one-size-fits-all’ HCV regimen into phase III

Comes shortly after Gilead wins priority FDA review for its 'pan-genotypic' treatment

- PMLiVE

ViiV and Janssen plan pivotal trials of monthly HIV treatment

Rilpivirine – cabotegravir combination could provide a monthly option

- PMLiVE

Up in smoke

The side-lining of efficacy in medical cannabis debates

- PMLiVE

Less is more: how risk-based monitoring is changing trials

A quality risk management approach is one of the biggest drivers for change in clinical research

- PMLiVE

It’s time for pharma companies to become household names

And then the sector can become meaningful to the lives of ‘ordinary’ people

- PMLiVE

Getting patients to engage with clinical trials

The EUPATI European initiative and increasing public knowledge of research

- PMLiVE

Counting down to the EFPIA Disclosure Code

Communications director Andy Powrie-Smith on why the Code is part of pharma's 'licence to operate'

- PMLiVE

Could EFPIA’s new code boost pharma’s reputation?

Rule changes for payments to doctors could present the industry with an opportunity

- PMLiVE

Harnessing clinical data

A greater focus on stakeholders could improve pharma's trial challenges

- PMLiVE

Transparency debate extends to rejected drug applications

Claims from the BMJ made in new published study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links